DRG Epidemiology’s coverage of non-small cell lung cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of non-small cell lung cancer for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s non-small cell lung cancer forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with non-small cell lung cancer each year?
  • Of all people diagnosed with non-small cell lung cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of non-small cell lung cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Note: Coverage may vary by country

Table of contents

  • Non-Small-Cell Lung Cancer - Epidemiology - Epidemiology Dashboard
    • Introduction
      • Non-Small-Cell Lung Cancer Epidemiology Dashboard

Author(s): Nishant Kumar, M.P.H.

Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


Related Reports

Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.

View Details

Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...

View Details

Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

View Details

Non-Small-Cell Lung Cancer - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estim...

View Details